Q2 2024 EPS Estimates for Halozyme Therapeutics, Inc. Increased by Leerink Partnrs (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) – Stock analysts at Leerink Partnrs raised their Q2 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Friday, June 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will earn $0.75 per share for the quarter, up from their previous forecast of $0.73. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.44 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q3 2024 earnings at $1.07 EPS.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million for the quarter, compared to analysts’ expectations of $201.72 million.

Several other analysts have also recently issued reports on HALO. JMP Securities dropped their target price on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, June 4th. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $48.00 to $51.00 in a research note on Friday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $54.13.

Check Out Our Latest Stock Report on HALO

Halozyme Therapeutics Stock Down 1.1 %

Shares of NASDAQ:HALO opened at $50.85 on Monday. Halozyme Therapeutics has a 52-week low of $32.78 and a 52-week high of $53.00. The stock has a market cap of $6.47 billion, a P/E ratio of 21.01, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. The business’s 50 day moving average is $41.88 and its 200 day moving average is $39.31. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 30,000 shares of company stock worth $1,255,100. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after acquiring an additional 152,870 shares during the period. TD Asset Management Inc boosted its holdings in Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after buying an additional 557,350 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Halozyme Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock worth $64,167,000 after buying an additional 37,763 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock worth $59,622,000 after buying an additional 145,879 shares during the last quarter. Finally, Stephens Investment Management Group LLC boosted its holdings in Halozyme Therapeutics by 4.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,518,455 shares of the biopharmaceutical company’s stock worth $56,122,000 after buying an additional 63,748 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.